Monograph
J07BH01 - Rota Virus, Live Attenuated |
Propably not porphyrinogenic |
PNP |
Side effects
Fever, diarrhea and vomiting are reported as very common side effects.
Rationale
Based on the pharmacokinetics of the rotavirus vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Live attenuated human rotavirus RIX4414 strain.
Therapeutic characteristics
The rotavirus vaccine is indicated for the active immunization of infants aged 6 to 24 weeks for prevention of gastro-enteritis due to rotavirus infection.
It is administered orally by a 2-dose regimen with an interval of at least 4 weeks. The first dose may be given from the age of 6 weeks must be completed by the age of 24 weeks (preferably before 16 weeks ).
Metabolism and pharmacokinetics
The rotavirus vaccine is not metabolized by the Cytochrome P450 system.
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
|
|
| * | Summary of Product Characteristics | |
| 2. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Rotarix. (Last edition: 14.01. 2016).
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia© NAPOS 2024